Novel treatment approaches for patients with multiple myeloma

Clinical Lymphoma & Myeloma
Rajni SinhaSagar Lonial

Abstract

Treatment options for patients with multiple myeloma are a rapidly progressing area of clinical and scientific development. The discovery of key signaling pathways needed for myeloma cell growth and proliferation has resulted in a plethora of new and different treatment options. Chief among these new agents are the proteasome inhibitor bortezomib and the immunomodulatory agents thalidomide and lenalidomide. Efficacy for these agents has been extensively studied in the relapsed and refractory states, and more recently in induction therapy. Impressive responses have been observed in the induction and relapsed disease states, completely changing the disease treatment paradigms. Building on these successes and strong preclinical work, other signal transduction inhibitors are being tested in phase I and phase II clinical trials. These include agents that target histone acetylation, farnesylation, heat shock proteins, and direct AKT-targeting agents. Additionally, monoclonal antibody targets are being developed in an effort to target the tumor cells extracellularly. Clinical trial development based on preclinically designed rational combinations and targets have the potential to rapidly translate these findings into meaningful clinic...Continue Reading

References

Jul 1, 1994·British Journal of Haematology·A VaccaF Dammacco
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Sep 20, 2000·Mayo Clinic Proceedings·S V RajkumarP R Greipp
Nov 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiSteven L Soignet
Jan 8, 2003·Blood·Liping HuAlan Lichtenstein
May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
Jun 5, 2003·British Journal of Haematology·Athanasios AnagnostopoulosRaymond Alexanian
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Choon-Kee LeeGuido Tricot
Mar 30, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Meletios A DimopoulosAthanasios Anagnostopoulos
Apr 2, 2004·Nature Reviews. Cancer·J Blake BartlettAngus G Dalgleish
Apr 20, 2004·Blood·Teru HideshimaKenneth C Anderson
May 4, 2004·Nature Reviews. Cancer·Julian Adams
Jul 14, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S A ScheyA G Dalgleish
Dec 1, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lynn Van UmmersenGeorge Wilding
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Jun 28, 2005·American Journal of Hematology·Michael WangRaymond Alexanian

❮ Previous
Next ❯

Citations

May 27, 2008·Clinical Lymphoma & Myeloma·S Pierson GladneyJonathan L Kaufman
Sep 23, 2008·Cellular Signalling·Michael LishnerLiat Drucker

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Expert Opinion on Investigational Drugs
Sara BringhenAntonio Palumbo
Expert Review of Anticancer Therapy
Noopur RajeKenneth C Anderson
© 2021 Meta ULC. All rights reserved